Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study

Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis

(2021) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY

Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain

(2021) Angel P. Sempere et al.   Frontiers in Neurology

Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia

(2020) Khalaf Kridin et al.   AUTOIMMUNITY REVIEWS

Worsening disability status in multiple sclerosis predicts urologic complications

(2020) Alejandro Abello et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Multiple cause of death analysis in multiple sclerosis

(2020) Katharine Harding et al.   NEUROLOGY

Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts – the CONFIDENCE study protocol

(2020) Petra Dirks et al.   BMC Neurology

P36 Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions

(2020) T. Derfuss et al.   CLINICAL NEUROPHYSIOLOGY

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

(2020) Wei-jie Guan et al.   EUROPEAN RESPIRATORY JOURNAL

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

(2020) Christopher M Petrilli et al.   BMJ-British Medical Journal

Ocrelizumab initiation in patients with MS

(2020) Erik Ellwardt et al.   Neurology-Neuroimmunology & Neuroinflammation

Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany

(2020) Sebastian Rauer et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients

(2020) Victoria Prockl et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension

(2020) Stephen L. Hauser et al.   NEUROLOGY

Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study

(2020) Mathias Due Buron et al.   NEUROLOGY

Ofatumumab versus Teriflunomide in Multiple Sclerosis

(2020) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis

(2020) Céline Louapre et al.   JAMA Neurology

Infections in patients diagnosed with multiple sclerosis: A multi-database study

(2020) R. Persson et al.   Multiple Sclerosis and Related Disorders

Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab

(2020) Michael Auer et al.   Multiple Sclerosis and Related Disorders

COVID-19 outcomes in MS

(2020) Erica Parrotta et al.   Neurology-Neuroimmunology & Neuroinflammation

Trends and characteristics of infection-related hospital admissions in multiple sclerosis patients in Southwest Finland in 2009–2018

(2020) Anna-Leena Pirttisalo et al.   Multiple Sclerosis and Related Disorders

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

(2020) Jerry S Wolinsky et al.   LANCET NEUROLOGY

Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population

(2020) Eva Fernandez‐Diaz et al.   Annals of Clinical and Translational Neurology

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

(2019) J. William L. Brown et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis

(2019) Katharine Harding et al.   JAMA Neurology

B cells in autoimmune and neurodegenerative central nervous system diseases

(2019) Joseph J. Sabatino et al.   NATURE REVIEWS NEUROSCIENCE

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

(2019) Gustavo Luna et al.   JAMA Neurology

Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature

(2019) Chiara Zanetta et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

(2018) E. C. Tallantyre et al.   JOURNAL OF NEUROLOGY

Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study

(2018) José Maria Andreas Wijnands et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients

(2018) Stefan Gingele et al.   Cells

Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab

(2017) Evangelos A.A. Christou et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012

(2017) Sarah Burkill et al.   NEUROLOGY

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Infection-related health care utilization among people with and without multiple sclerosis

(2016) José MA Wijnands et al.   Multiple Sclerosis Journal

Long-lived antigen-induced IgM plasma cells demonstrate somatic mutations and contribute to long-term protection

(2016) Caitlin Bohannon et al.   Nature Communications

Infection-related health care utilization among people with and without multiple sclerosis

(2016) José MA Wijnands et al.   Multiple Sclerosis Journal

Long-Lived Plasma Cells Are Contained within the CD19−CD38hiCD138+ Subset in Human Bone Marrow

(2015) Jessica L. Halliley et al.   IMMUNITY

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

(2015) R. F. van Vollenhoven et al.   JOURNAL OF RHEUMATOLOGY

Effect of comorbidity on mortality in multiple sclerosis

(2015) Ruth Ann Marrie et al.   NEUROLOGY

Respiratory dysfunction in multiple sclerosis

(2015) George E. Tzelepis et al.   RESPIRATORY MEDICINE

Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients

(2014) Arumugam Palanichamy et al.   JOURNAL OF IMMUNOLOGY

Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program

(2014) Paul Emery et al.   PLoS One

Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics

(2012) Inmaculada De La Torre et al.   RHEUMATOLOGY

Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms

(2011) Daniel Tesfa et al.   Expert Review of Hematology

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

(2010) J.-E. Gottenberg et al.   ARTHRITIS AND RHEUMATISM

Selective IgA Deficiency

(2010) Leman Yel   JOURNAL OF CLINICAL IMMUNOLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

B cells and multiple sclerosis

(2008) Diego Franciotta et al.   LANCET NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Maintenance of the plasma cell pool is independent of memory B cells

(2008) A. Ahuja et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA